Physician profile
Allyson E Mcclain
NPI 1871972109
$5,873.22
in general payments reported to CMS, 2019-2025
40 companies · $843 in 2025
The $843 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $1,158 · 2023: $1,431 · 2024: $1,332 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $874.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $781.69 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $662.89 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $526.35 | 2021-2025 | |
| Amgen INC. | $359.06 | 2021-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.77 | 2021-2024 | Jardiance, Tradjenta, Ofev |
| Pfizer INC. | $244.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $158.52 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $143.34 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Dexcom, INC. | $132.39 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $122.92 | 2023-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $104.08 | 2024-2025 | Korlym |
| Ibsa Pharma INC. | $99.33 | 2021-2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company Ltd. | $95.03 | 2022 | |
| Glaxosmithkline, LLC. | $94.76 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.